Other languages Johnson & Johnson Xetra

Equities

JNJ

US4781601046

Market Closed - Xetra Other stock markets 09:05:53 31/05/2024 pm IST			5-day change	1st Jan Change
135.2 ^EUR	+1.02%		-1.10%	-4.57%

02/06	GSK blood cancer drug nearly halves risk of death in late-stage trial	RE
01/06	US lawmakers ask FBI for briefing on GenScript Biotech's links to China	RE

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GSK blood cancer drug nearly halves risk of death in late-stage trial	02/06
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	01/06
Sector Update: Health Care Stocks Higher Late Afternoon	01/06
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	01/06
Sector Update: Health Care Stocks Advance Friday Afternoon	31/05
Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars	31/05
Johnson & Johnson Executive Vice President, William N. Hait, M.D., Ph.D., to Retire, Effective September 2024	31/05
J&J : finalise l'acquisition de Shockwave Medical	31/05
Johnson & Johnson Closes Acquisition of Shockwave Medical	31/05
Johnson & Johnson Completes Acquisition of Shockwave Medical	31/05
Johnson & Johnson Completes Acquisition of Shockwave Medical	31/05
Johnson & Johnson completed the acquisition of Shockwave Medical, Inc. from a group of sellers.	31/05
Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	30/05
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Press Release	30/05
Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM	29/05
J&J : résultats encourageants dans le soin de la dépression	29/05
Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints	29/05
J&J's treatment for depression succeeds in late stage study	29/05
Johnson & Johnson Announces Pivotal Study of Seltorexant Shows Statistically Significant and Clinically Meaningful Improvement in Depressive Symptoms and Sleep Disturbance Outcomes	29/05
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	29/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST